BCMA GoCAR-NK cell therapy / Bellicum - LARVOL DELTA

Bellicum Reports Second Quarter 2020 Financial Results and Provides Operational Update (GlobeNewswire) - "BPX-603 GoCAR-T: BPX-603 is the company’s first dual-switch GoCAR-T product candidate, which incorporates both the company’s iMC activation and CaspaCIDe^® safety switch technologies and the company plans to initiate a Phase 1/2 basket trial in solid tumors that express HER2 later this year...BCMA GoCAR-NK™ Program: Management expects to present additional preclinical data for this program by the end of 2020.:"

New P1 trial • Preclinical • Hematological Malignancies • Multiple Myeloma • Oncology • Solid Tumor

Bellicum announces publication of data for GoCAR-NK cell program (GlobeNewswire) - "Bellicum Pharmaceuticals...announced the publication of preclinical data from its GoCAR-NK™ Cell Program in the digital edition of Blood Advances, a journal published by The American Society of Hematology...In this study, incorporating iMC into CAR-NK cells was found to improve cell proliferation and persistence, stimulate cytokine production, and enhance innate cytotoxicity against tumor cells in multiple models...'Based on these findings, we have nominated our first GoCAR-NK program targeting BCMA for preclinical development and expect to present additional data later this year'.”"

Preclinical • Oncology

Bellicum reports first quarter 2020 financial results and provides operational update (GlobeNewswire) - "Bellicum continues to conduct its investigational work in preparation of its response to the FDA’s request to further characterize this product candidate and support potential IND clearance. Management expects to provide an update on its progress for this program in the third quarter of 2020....BCMA GoCAR-NK™ Program: Management expects to present additional preclinical data for this program by the end of 2020."

IND • Preclinical • Hematological Malignancies • Multiple Myeloma • Oncology • Solid Tumor